Cite
MLA Citation
Tianxing Zhou et al.. “ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.” Gut, vol. 71, no. 2, 2022, pp. 357–371. http://access.bl.uk/ark:/81055/vdc_100148213428.0x000057